HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK 818033 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 189.9M shares as of Aug 5, 2026 (10-Q). Share count fell from 313.6M to 23.7M between Oct 31, 2013 and Feb 28, 2014, a pattern consistent with a reverse split (roughly 1-for-13); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
Warrants outstanding: 220,164 underlying shares, as reported Dec 31, 2020 (10-K).
Rough fully diluted estimate: 190.1M = 189.9M O/S + 220,164 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Two Thousand Thirty One Senior Unsecured Convertible Notes | $35.0M | $35.0M | $555.5556 | 5% | ~63,000 sh |
| Two Thousand Twenty Six Senior Unsecured Convertible Notes | not tagged | $0 | not tagged | — | — |
If every note above converted at its tagged price: ~63,000 new shares on 189.9M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 10, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 189.9M | Aug 5, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 220,164 | Dec 31, 2020 |
| + Two Thousand Thirty One Senior Unsecured Convertible Notes (if fully converted) | 63,000 | Jun 30, 2026 |
| Fully diluted estimate | 190.1M | +0.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $175.4Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 0 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full HRTX workspace